12 research outputs found

    A High-Performance Gate Engineered InGaN Dopingless Tunnel FET

    No full text

    Production of <it>N</it><sup><it>Ī±</it></sup>-acetylated thymosin Ī±1 in <it>Escherichia coli</it>

    No full text
    Abstract Background Thymosin Ī±1 (TĪ±1), a 28-amino acid NĪ±-acetylated peptide, has a powerful general immunostimulating activity. Although biosynthesis is an attractive means of large-scale manufacture, to date, TĪ±1 can only be chemosynthesized because of two obstacles to its biosynthesis: the difficulties in expressing small peptides and obtaining NĪ±-acetylation. In this study, we describe a novel production process for NĪ±-acetylated TĪ±1 in Escherichia coli. Results To obtain recombinant NĪ±-acetylated TĪ±1 efficiently, a fusion protein, TĪ±1-Intein, was constructed, in which TĪ±1 was fused to the N-terminus of the smallest mini-intein, Spl DnaX (136 amino acids long, from Spirulina platensis), and a His tag was added at the C-terminus. Because TĪ±1 was placed at the N-terminus of the TĪ±1-Intein fusion protein, TĪ±1 could be fully acetylated when the TĪ±1-Intein fusion protein was co-expressed with RimJ (a known prokaryotic NĪ±-acetyltransferase) in Escherichia coli. After purification by Ni-Sepharose affinity chromatography, the TĪ±1-Intein fusion protein was induced by the thiols Ī²-mercaptoethanol or d,l-dithiothreitol, or by increasing the temperature, to release TĪ±1 through intein-mediated N-terminal cleavage. Under the optimal conditions, more than 90% of the TĪ±1-Intein fusion protein was thiolyzed, and 24.5 mg TĪ±1 was obtained from 1 L of culture media. The purity was 98% after a series of chromatographic purification steps. The molecular weight of recombinant TĪ±1 was determined to be 3107.44 Da by mass spectrometry, which was nearly identical to that of the synthetic version (3107.42 Da). The whole sequence of recombinant TĪ±1 was identified by tandem mass spectrometry and its N-terminal serine residue was shown to be acetylated. Conclusions The present data demonstrate that NĪ±-acetylated TĪ±1 can be efficiently produced in recombinant E. coli. This bioprocess could be used as an alternative to chemosynthesis for the production of TĪ±1. The described methodologies may also be helpful for the biosynthesis of similar peptides.</p

    Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in HER2ā€positive gastric cancer

    No full text
    Abstract Background Trastuzumab is a firstā€line targeted therapy for human epidermal growth factor receptorā€2 (HER2)ā€positive gastric cancer. However, the inevitable occurrence of acquired trastuzumab resistance limits the drug benefit, and there is currently no effective reversal measure. Existing researches on the mechanism of trastuzumab resistance mainly focused on tumor cells themselves, while the understanding of the mechanisms of environmentā€mediated drug resistance is relatively lacking. This study aimed to further explore the mechanisms of trastuzumab resistance to identify strategies to promote survival in these patients. Methods Trastuzumabā€sensitive and trastuzumabā€resistant HER2ā€positive tumor tissues and cells were collected for transcriptome sequencing. Bioinformatics were used to analyze cell subtypes, metabolic pathways, and molecular signaling pathways. Changes in microenvironmental indicators (such as macrophage, angiogenesis, and metabolism) were verified by immunofluorescence (IF) and immunohistochemical (IHC) analyses. Finally, a multiā€scale agentā€based model (ABM) was constructed. The effects of combination treatment were further validated in nude mice to verify these effects predicted by the ABM. Results Based on transcriptome sequencing, molecular biology, and in vivo experiments, we found that the level of glutamine metabolism in trastuzumabā€resistant HER2ā€positive cells was increased, and glutaminase 1 (GLS1) was significantly overexpressed. Meanwhile, tumorā€derived GLS1 microvesicles drove M2 macrophage polarization. Furthermore, angiogenesis promoted trastuzumab resistance. IHC showed high glutamine metabolism, M2 macrophage polarization, and angiogenesis in trastuzumabā€resistant HER2ā€positive tumor tissues from patients and nude mice. Mechanistically, the cell division cycle 42 (CDC42) promoted GLS1 expression in tumor cells by activating nuclear factor kappaā€B (NFā€ĪŗB) p65 and drove GLS1 microvesicle secretion through IQ motifā€containing GTPaseā€activating protein 1 (IQGAP1). Based on the ABM and in vivo experiments, we confirmed that the combination of antiā€glutamine metabolism, antiā€angiogenesis, and proā€M1 polarization therapy had the best effect in reversing trastuzumab resistance in HER2ā€positive gastric cancer. Conclusions This study revealed that tumor cells secrete GLS1 microvesicles via CDC42 to promote glutamine metabolism, M2 macrophage polarization, and proā€angiogenic function of macrophages, leading to acquired trastuzumab resistance in HER2ā€positive gastric cancer. A combination of antiā€glutamine metabolism, antiā€angiogenesis, and proā€M1 polarization therapy may provide a new insight into reversing trastuzumab resistance

    Bone-targeted nanoplatform enables efficient modulation of bone tumor microenvironment for prostate cancer bone metastasis treatment

    No full text
    As there is currently no effective therapy for patients with prostate cancer (PCa) bone metastasis, it was stringent to explore the relevant treatment strategies. Actually, the interaction between cancer cells and bone microenvironment plays important role in prostate cancer bone metastasis, especially the Sonic hedgehog protein (SHH) signaling in the bone microenvironment. The SHH promotes osteoblast maturation and osteoblast then secretes RANKL to induce osteoclastogenesis. Herein, this study develops bone-targeting calcium phosphate lipid hybrid nanoparticles (NPs) loaded with docetaxel (DTXL) and SHH siRNA for PCa bone metastasis treatment. For bone targeting purposes, the nanoplatform was modified with alendronate (ALN). (DTXL + siRNA)@NPs-ALN NPs effectively change the bone microenvironment by inhibiting the SHH paracrine and autocrine signaling, enhancing the anti-tumor effects of DTXL. Besides showing good in vitro cellular uptake, the NPs-ALN also inhibited tumor growth both in vitro and in vivo by inducing apoptosis, cell cycle arrest, and autophagy. This DDS comprised of (DTXL + siRNA)-loaded NPs provides an excellent strategy to treat PCa bone metastasis

    Bone-targeted nanoplatform enables efficient modulation of bone tumor microenvironment for prostate cancer bone metastasis treatment

    No full text
    As there is currently no effective therapy for patients with prostate cancer (PCa) bone metastasis, it was stringent to explore the relevant treatment strategies. Actually, the interaction between cancer cells and bone microenvironment plays important role in prostate cancer bone metastasis, especially the Sonic hedgehog protein (SHH) signaling in the bone microenvironment. The SHH promotes osteoblast maturation and osteoblast then secretes RANKL to induce osteoclastogenesis. Herein, this study develops bone-targeting calcium phosphate lipid hybrid nanoparticles (NPs) loaded with docetaxel (DTXL) and SHH siRNA for PCa bone metastasis treatment. For bone targeting purposes, the nanoplatform was modified with alendronate (ALN). (DTXL + siRNA)@NPs-ALN NPs effectively change the bone microenvironment by inhibiting the SHH paracrine and autocrine signaling, enhancing the anti-tumor effects of DTXL. Besides showing good in vitro cellular uptake, the NPs-ALN also inhibited tumor growth both in vitro and in vivo by inducing apoptosis, cell cycle arrest, and autophagy. This DDS comprised of (DTXL + siRNA)-loaded NPs provides an excellent strategy to treat PCa bone metastasis
    corecore